Company's Revenue Sees Slight Increase in Q1 2025 | CCEL Stock News

Author's Avatar
Apr 15, 2025
Article's Main Image

The company reported its financial results for the first quarter of fiscal year 2025, revealing a modest rise in total revenue. The overall revenue for this period reached $7.97 million, up from $7.85 million recorded in the same quarter of the previous fiscal year.

A detailed breakdown of the figures shows that revenue from processing and storage fees contributed $7.87 million. This marks a slight improvement over the $7.81 million earned from the same source in the first quarter of fiscal 2024. Product revenue also saw a notable increase, climbing to $21,000 from $3,000 year-over-year. Additionally, public banking revenue experienced growth, amounting to approximately $82,000, compared to $44,000 for the same period last year.

The company's financial performance in the first quarter reflects an upward trend, driven mainly by increases in processing and storage fees and significant gains in product and public banking revenues.

Wall Street Analysts Forecast

1912141630857703424.png

Based on the one-year price targets offered by 1 analysts, the average target price for Cryo-Cell International Inc (CCEL, Financial) is $8.50 with a high estimate of $8.50 and a low estimate of $8.50. The average target implies an upside of 55.11% from the current price of $5.48. More detailed estimate data can be found on the Cryo-Cell International Inc (CCEL) Forecast page.

Based on the consensus recommendation from 1 brokerage firms, Cryo-Cell International Inc's (CCEL, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Based on GuruFocus estimates, the estimated GF Value for Cryo-Cell International Inc (CCEL, Financial) in one year is $6.59, suggesting a upside of 20.26% from the current price of $5.4799. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Cryo-Cell International Inc (CCEL) Summary page.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.